Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of interleukin-11 to prevent immune-mediated cytotoxicity

a technology of interleukin-11 and cytotoxicity, which is applied in the direction of immunological disorders, drug compositions, peptide/protein ingredients, etc., can solve the problems of depletion of bone marrow grafts, higher graft failure rate, and recipient at risk of graft-versus-host diseas

Inactive Publication Date: 2006-03-23
GENETICS INST INC +1
View PDF15 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes the discovery of a protein called IL-11 that can protect endothelial cells from damage caused by immune cells and other factors. This protein can be administered to patients to prevent or treat diseases such as graft versus host disease and rejection of organ transplants. It can also be used to treat non-immune-related injuries such as necrotic tissue damage. The patent provides methods for administering IL-11 to patients and suggests that it can be used alone or in combination with other drugs to alleviate symptoms of these diseases. The therapeutic dose is typically between 1 to 100 μg / kg body weight.

Problems solved by technology

Thus, when MHC antigenic differences exist between the donor and recipient, the recipient is at risk for the development of graft-versus-host disease.
However, use of bone marrow depleted of T cells is associated with a higher rate of graft failure, which is frequently fatal.
Use of T cell depleted bone marrow grafts is also associated with an increased incidence of relapse among the recipients, particularly recipients having chronic myelocytic leukemia.
However, antibody depletion has unacceptable risks of over-immunosuppression (i.e., infection), and experimental studies of inhibition of the complement cascade with cobra venom factor or sCR1 show incomplete inhibition.
An additional drawback to the use of cobra venom is the prospect of systemic effects due to the large amounts of vasoactive and chemotactic C3a and C5a produced.
However, immunosuppression also results in increased incidence of infection, and even when immunosuppressant drugs are used, immune-mediated cytotoxicity may still occur.
Although many approaches to controlling immune-mediated disorders have been attempted, none of these approaches have been particularly successful.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of interleukin-11 to prevent immune-mediated cytotoxicity
  • Use of interleukin-11 to prevent immune-mediated cytotoxicity
  • Use of interleukin-11 to prevent immune-mediated cytotoxicity

Examples

Experimental program
Comparison scheme
Effect test

example 1

Dose and Time Dependent Phosphorylation by IL-11

[0060] 4 μg of total RNA from cultured HUVECs, CACO-2 or K562 cells was incubated over night with probes for human IL-11Rα chain and GAPDH genes. Samples were digested with RnbaseA / T1 and protected fragments (321 bp for IL-11Rα and 96 bp for GAPDH were resolved on a 6% acylamide / TBE-Urea gel. Lysates from either HUVECs or K562 cells were resolved on SDS-PAGE as described above and immunoblotted with specific antibody to IL-11 receptor a chain. The IL-11 receptor a chain was detected in HUVECs and K562 cells at about MW 83 kD.

[0061] Next, HUVECs were either untreated (control), treated with IL-11 (100 ng / ml), or oncostatin M (20 ng / ml) for 2 min and 10 min. Cell lysates were immunoprecipitated with specific antibody to gp130. Immune complexes were resolved on SDS-PAGE and immunoblotted with a phosphotyrosine specific antibody as described above. The results indicate that IL-11 tyrosine phosphorylates gp130 in HUVECs.

[0062] To test wh...

example 2

The IL-11 Receptor Alpha Chain is Expressed on B and T Lymphocytes

[0066] Murine B Cells and CD4+ and CD8+ T cells were purified from Balb / c spleens using positive selection with MACS (Magnetic Cell Sorting) Microbeads conjugated to anti-mouse B220, CD4 or CD8 antibodies, as per manufacturers protocol (Miltenyi Biotec, Sunnyvale, Calif.). RNA was extracted from purified cell populations as described above using RNA Stat-60 (Tel-test, Inc., TX) as per manufacturer's protocol. RNA was DNase treated (RQ1 DNase, Promega, Madison, Wis.) for 30 min at 37° C., then heat inactivated for 5 min at 75° C. RT-PCR was performed (GeneAmp RNA PCR Kit, Perkin Elmer) using 40 ng RNA (10 ng for GAPDH) and oligo pairs specific for murine GAPDH, IL-11 receptor a chain, IL-10 receptor, IL-6 receptor or gp130, and visualized on an ethidium-stained agarose gel. PCR reactions on RNA samples in the absence of reverse transcriptase were negative for each oligo pair, and served as a control for DNA contaminat...

example 3

IL-11 Increases Antigen Specific Cytolytic Activity in Bulk Spleen Cultures

[0067] Seven day splenic bulk cultures from cells treated with IL-2, or IL-2 and IL-11, were serially diluted and added to 1×104 51Cr-labelled P815.P1HTR cells, which were pulsed for one hour in the presence or absence of NP peptide. The cells were incubated for 4 hours. Supernatants were harvested, and 51Cr release was determined. Maximum lysis on the target cells was induced with 2% Triton-X 100. % lysis=[(CPM−spontaneous CPM of NP peptide pulsed targets) / (maximum CPM of NP peptide pulsed targets−spontaneous CPM of NP peptide pulsed targets)]×100. % specific lysis=(% lysis on NP peptide pulsed target cells)−(% lysis of control target cells). The example indicates that IL-11 can significantly enhance the % specific lytic activity of NP peptide-specific cytotoxic T cells. At a 50:1 effector to target cell ratio, a 250% enhancement in % specific lysis is observed in cells treated with IL-2 and IL-11 versus ce...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.

Description

FIELD OF INVENTION [0001] The present invention relates to the field of prevention and treatment of immune-mediated disorders using interleukin-11. More particularly, the present invention relates to preventing or treating graft-versus-host disease and CTL- and / or complement-dependent rejection of organ or tissue transplants using interleukin-11. BACKGROUND OF THE INVENTION [0002] An individual mammal's immune system functions through recognition of certain cell surface proteins, some of which are termed major histocompatibility complex proteins, or MHC proteins. Additional minor histocompatibility proteins exist which can also contribute to immunological recognition events. The individual mammal's immune system recognizes its own MHC proteins, or those of its identical twin, as self and thus does not destroy its own cells or those of its identical twin. Members of the same species may share major and / or minor histocompatibility antigens, and thus an individual may not recognize the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/19A61K38/20
CPCY10S514/885A61K38/2073A61P37/02
Inventor KEITH, JAMESCARROLL, JOSEPH M.POBER, JORDAN S.
Owner GENETICS INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com